Denosumab in early breast cancer: negative data and a call to action

Lancet Oncol. 2020 Jan;21(1):5-6. doi: 10.1016/S1470-2045(19)30717-X. Epub 2019 Dec 2.

Authors

Francesco Perrone¹, Adriano Gravina²

Affiliations

¹ Clinical Trial Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori IRCCS Fondazione G Pascale, Naples 80131, Italy. Electronic address: f.perrone@istitutotumori.na.it.
² Clinical Trial Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori IRCCS Fondazione G Pascale, Naples 80131, Italy.

PMID: 31806541
DOI: 10.1016/S1470-2045(19)30717-X

No abstract available

Publication types

Comment

MeSH terms

Adjuvants, Immunologic
Bone Density Conservation Agents*
Breast Neoplasms*
Denosumab
Humans

Substances

Adjuvants, Immunologic
Bone Density Conservation Agents
Denosumab